预约演示
更新于：2025-05-07
Bevacizumab
贝伐珠单抗
更新于：2025-05-07
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、加速批准 (美国)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 41632H
来源: *****
Sequence Code 41637L
来源: *****
关联
3,144
项与 贝伐珠单抗 相关的临床试验NCT05375708
A Multicenter Phase II Randomized Trial to Evaluate Systemic Therapy Versus Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer
NCT05956821
Phase I/II Trial of Repeat Dosing of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
NCT06948448
A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
100 项与 贝伐珠单抗 相关的临床结果
登录后查看更多信息
100 项与 贝伐珠单抗 相关的转化医学
登录后查看更多信息
100 项与 贝伐珠单抗 相关的专利（医药）
登录后查看更多信息
23,340
项与 贝伐珠单抗 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer
Article
作者: Appukkuttan, Sreevalsa ; Cho, Sang Kyu ; Barzi, Afsaneh ; Grossman, Jamie ; Lee, Woojung ; Babajanyan, Svetlana ; Hocum, Brian ; Marian, Marisca ; Yang, Min ; Bekaii-Saab, Tanios
BACKGROUND:
New regimens have emerged as third-line or later therapies for metastatic colorectal cancer (mCRC), including regorafenib dose optimization (ReDO), trifluridine/tipiracil and bevacizumab (TAS-BEV) combination therapy, and fruquintinib. We evaluated relative cost-effectiveness of these therapies in patients with mCRC from a US payer's perspective.
MATERIALS AND METHODS:
A partitioned survival model (PSM) was constructed to estimate total costs and quality-adjusted life years (QALYs). Clinical parameters were obtained from pivotal trials of the respective therapies and incremental cost-effectiveness ratios (ICERs) were estimated to assess relative cost-effectiveness of these treatments. Model robustness was assessed using deterministic (DSA) and probabilistic sensitivity analysis (PSA). Three scenario analyses were conducted: (1) assuming equal efficacy across treatments, (2) with prior exposure to anti-vascular endothelial growth factor (VEGF) therapy, and (3) alternative clinical inputs for fruquintinib from a different clinical trial.
RESULTS:
Under the conventional willingness-to-pay (WTP) threshold in US ($150,000 per QALY gained), ReDO was cost-effective when compared with TAS-BEV and was dominant over fruquintinib. TAS-BEV was associated with an incremental QALY of 0.197 over ReDO, resulting in an ICER at $554,567 per QALY gained. The base case results were robust in DSA and PSA. Most influential parameters were treatment cost and effectiveness. In patients with prior anti-VEGF therapy, ReDO remained cost-effective compared to TAS-BEV and fruquintinib under the conventional WTP threshold.
LIMITATION:
Differences in trial populations may affect the comparability of the outcomes. Sensitivity and scenario analyses were conducted to address these limitations.
CONCLUSION:
ReDO was cost-effective compared with TAS-BEV from the US payer's perspective despite a higher QALY gain associated with TAS-BEV. ReDO was dominant over fruquintinib, consistently having a higher QALY gain and lower cost.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-efficiency and expanded access modeling of conversion to biosimilar bevacizumab in metastatic colorectal and non-squamous non-small cell lung cancer in Medicare
Article
作者: Bernauer, Mark ; Roth, Joshua A. ; Dorman, Stephanie ; Kratochvil, David
BACKGROUND:
Biosimilars to originator bevacizumab (Avastin), such as bevacizumab-bvzr (Zirabev), can deliver substantial savings and/or expanded access to biologic therapy for patients with metastatic colorectal (mCRC) and non-squamous non-small cell lung cancer (mNSCLC). The objective of this study is to explore the cost-efficiency and budget-neutral expanded access of bevacizumab-bvzr in mCRC and mNSCLC in Medicare.
METHODS:
We developed a Medicare payer perspective simulation model of patients treated for mCRC and mNSCLC to estimate cost-savings from converting bevacizumab (originator) to bevacizumab-bvzr or alternative biosimilars such as bevacizumab-awwb, -maly, and -abcd. The target patient population receiving annual first-line systemic therapy was calculated using Medicare enrollment data, SEER cancer incidence rates in patients age ≥65, and an assumption that 39.3% and 77.2% of new diagnoses receive systemic therapy for mCRC and mNSCLC respectively based on recent evidence. 76.0% of systemically treated mCRC patients and 11.4% of incident mNSCLC patients were expected to be treated with bevacizumab-based regimens based on recent evidence. Costs were derived from the 2024 Average Sales Price (ASP). Results include per-patient per-month (PPPM) cost savings (vs. originator), total monthly savings in the cohort, and number needed to convert (NNC) to biosimilar to fund the treatment of an additional 100 patients.
RESULTS:
PPPM savings from conversion to bevacizumab-bvzr were $4,205 in mCRC and $8,410 in mNSCLC. In 100% conversion scenarios, full cohort monthly savings were $27,664,432 in mCRC (n = 6,579) and $32,319,323 in mNSCLC (n = 3,843), respectively. At 100% conversion, monthly savings from biosimilar conversion could fund up to 13,887 additional mCRC patient-months of treatment with bevacizumab-bvzr + FOLFOX, and up to 8,959 additional mNSCLC patient-months of treatment with bevacizumab-bvzr + paclitaxel + carboplatin. In mCRC and mNSCLC the biosimilar NNC from the originator was 47 and 43, respectively. The biosimilar NNC from other biosimilars ranged from 60-4,564 and 55-4,422 for mCRC and NSCLC, respectively.
CONCLUSION:
In the first cost-efficiency and expanded access study of biosimilar bevacizumab in mCRC and mNSCLC, we find that bevacizumab-bvzr-based regimens can result in substantial cost savings relative to originator-based first line treatment in Medicare. These cost savings could be reinvested to treat a substantial number of additional patients with mCRC or mNSCLC, or fund other costs of care in Medicare, on a budget-neutral basis.
2025-12-31Journal of Pharmaceutical Policy and Practice
Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
Article
作者: Wang, Jinglin ; Wang, Chunping ; Zhang, Qilin ; Ding, Yiling ; Shu, Yamin
Background:
The addition of cadonilimab to first-line platinum-based chemotherapy with or without bevacizumab significantly improved progression-free survival (PFS) and overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer. However, the economic value of using this novel therapy for this indication is currently unknown. The aim of this study is to evaluate the cost-effectiveness of the addition of cadonilimab to first-line standard chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer from the perspective of Chinese healthcare system.
Methods:
A partitioned survival model was constructed to compare the cost-effectiveness of cadonilimab versus placebo in patients enrolled in the COMPASSION-16 trial. Cost, life-year, quality-adjusted life-year (QALY), incremental cost-effectiveness ratio (ICER), incremental net health benefit (INHB), and incremental net monetary benefit (INMB) were calculated for 2 treatment strategies. Sensitivity, scenario, and subgroup analyses, and value of information analysis (EVPI) were performed.
Results:
Cadonilimab provided an additional 1.18 QALYs and $89,528.64 compared with placebo, which resulted in an ICER of $75,944.56/QALY. At the willingness-to-pay threshold of $38,042.49/QALY, INHB was estimated to be -1.17 QALYs, while INMB amounted to -$44,681.55 and EVPI was calculated as $71.40/person. Sensitivity analyses revealed that the model was most sensitive to hazard ratio (HR) for OS and PFS, and the probability of cadonilimab being cost-effective was 0.70%. To achieve cost-effectiveness, the price of cadonilimab must be reduced by approximately 50%. Subgroup analysis found that all subgroups unfavored cadonilimab by varying the HR for OS and PFS. Scenario analyses showed using life-year as effectiveness, altering time horizon and selection of survival analysis did not reverse results.
Conclusions:
Although the use of cadonilimab resulted in clinical benefit, it was not deemed cost-effective as a first-line therapy for persistent, recurrent, or metastatic cervical cancer in China. Lowering the price of cadonilimab may enhance its cost-effectiveness.
2,693
项与 贝伐珠单抗 相关的新闻（医药）8 小时之前
临床结果ASCO会议临床2期临床1期
8 小时之前
临床结果ASCO会议临床3期抗体药物偶联物
100 项与 贝伐珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不可切除的肝细胞癌 | 日本 | 2020-09-25 | |
| 肝细胞癌 | 美国 | 2020-05-29 | |
| 复发性胶质母细胞瘤 | 美国 | 2020-05-29 | |
| 复发性原发性腹膜癌 | 美国 | 2014-11-14 | |
| 卵巢癌 | 日本 | 2013-11-22 | |
| 胶质瘤 | 日本 | 2013-06-14 | |
| 乳腺癌 | 日本 | 2011-09-26 | |
| 结直肠癌 | 日本 | 2009-09-18 | |
| 转移性肾细胞癌 | 美国 | 2009-07-31 | |
| 胶质母细胞瘤 | 美国 | 2009-05-05 | |
| 转移性结直肠癌 | 美国 | 2009-05-05 | |
| 节细胞神经胶质瘤 | 日本 | 2007-04-18 | |
| 非鳞状非小细胞肺癌 | 美国 | 2006-10-11 | |
| 输卵管癌 | 欧盟 | 2005-01-12 | |
| 输卵管癌 | 冰岛 | 2005-01-12 | |
| 输卵管癌 | 列支敦士登 | 2005-01-12 | |
| 输卵管癌 | 挪威 | 2005-01-12 | |
| 转移性乳腺癌 | 欧盟 | 2005-01-12 | |
| 转移性乳腺癌 | 冰岛 | 2005-01-12 | |
| 转移性乳腺癌 | 列支敦士登 | 2005-01-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 晚期头颈癌 | 临床3期 | 美国 | 2023-03-13 | |
| 头颈部皮肤鳞状细胞癌 | 临床3期 | 美国 | 2023-03-13 | |
| 头颈癌转移 | 临床3期 | 美国 | 2023-03-13 | |
| 鼻咽癌 | 临床3期 | 美国 | 2023-03-13 | |
| 鼻咽鳞状细胞癌 | 临床3期 | 美国 | 2023-03-13 | |
| 口咽肿瘤 | 临床3期 | 美国 | 2023-03-13 | |
| 复发性咽部鳞状细胞癌 | 临床3期 | 美国 | 2023-03-13 | |
| 复发性头颈部鳞状细胞癌 | 临床3期 | 美国 | 2023-03-13 | |
| 早产儿视网膜病变 | 临床3期 | 美国 | 2022-04-27 | |
| 早产儿视网膜病变 | 临床3期 | 加拿大 | 2022-04-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 艱夢夢積鑰遞齋膚顧廠 = 簾願範膚觸簾繭襯鏇鏇 夢夢壓繭繭淵鏇窪構積 (壓衊獵鑰夢壓糧鬱製繭, 蓋壓艱繭遞夢鹹窪簾壓 ~ 簾壓窪鏇鹹範窪網簾蓋) 更多 | - | 2025-04-02 | |||
临床2期 | 38 | 糧鹽鬱製製遞淵鏇齋範(製鏇憲築蓋製築衊鹹積) = 製餘製範蓋構齋繭鬱積 願積艱蓋獵鹽壓製範範 (積夢鑰築壓鏇夢襯艱簾, 窪鑰遞夢選壓齋窪遞鹽 ~ 鹽鏇願夢衊鬱築選鹹選) 更多 | - | 2025-03-28 | |||
临床2/3期 | 444 | (Arm I (PLD, Atezolizumab)) | 膚築遞繭窪衊壓構膚窪 = 願鏇糧顧鏇淵夢鬱膚夢 範獵醖鑰醖構艱衊襯襯 (鏇觸窪範衊糧鬱繭鏇積, 製鑰顧繭觸窪鬱構艱夢 ~ 憲製簾積糧襯餘壓獵簾) 更多 | - | 2025-03-04 | ||
(Arm II (PLD, Bevacizumab, Atezolizumab)) | 膚築遞繭窪衊壓構膚窪 = 蓋襯積鹹願鏇淵顧窪鹽 範獵醖鑰醖構艱衊襯襯 (鏇觸窪範衊糧鬱繭鏇積, 顧壓積齋憲顧鏇壓構蓋 ~ 鹹艱淵蓋鹽襯獵齋膚糧) 更多 | ||||||
临床2期 | 44 | (Safety Lead in Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine)) | 襯襯鏇糧醖淵繭範襯艱 = 憲餘鬱鑰夢醖醖蓋選範 構網鑰鏇簾廠蓋壓鑰廠 (構繭網蓋範淵鹽艱積醖, 夢網廠觸鹽網憲願醖鏇 ~ 淵衊餘遞夢餘糧鬱簾鏇) 更多 | - | 2025-02-28 | ||
(Expansion Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine)) | 鏇糧膚艱願鬱艱獵齋製(繭壓廠廠網鹽餘簾襯網) = 獵醖憲鑰網顧簾積獵構 餘餘壓鏇淵醖鬱遞餘襯 (製簾遞餘憲顧醖願廠衊, 範選鏇壓壓顧範獵壓鑰 ~ 醖網鏇製夢憲餘齋築繭) 更多 | ||||||
临床2期 | 25 | NovoTTF-l00A+Bevacizumab | 積淵窪積網餘廠艱願艱 = 窪夢窪選膚願壓鬱憲膚 構選願餘艱餘淵鹹鑰蓋 (範積製夢積範鏇鑰襯餘, 願廠壓憲願鹹範鏇積蓋 ~ 憲鑰積繭醖衊鹹憲襯蓋) 更多 | - | 2025-02-17 | ||
临床3期 | 149 | 憲顧構衊願鬱鏇鏇衊獵(構襯範簾淵襯鹽範遞蓋) = bleeding/hemorrhages was 11.4% 網構願襯夢淵鬱選蓋觸 (鹹積構醖窪艱選鹹觸顧 ) | 积极 | 2025-02-01 | |||
临床2期 | RAS 野生型结直肠癌 RAS wild-type | 359 | m-FOLFOXIRI plus cetuximab | 淵鹽顧餘遞窪鑰築製顧(醖願夢簾繭鏇獵壓壓糧) = 鑰醖網範簾鹹網衊製鑰 選鹽憲膚鏇鹹觸繭繭願 (獵壓壓膚構鏇醖襯衊遞 ) 更多 | 积极 | 2025-01-23 | |
m-FOLFOXIRI plus bevacizumab | 淵鹽顧餘遞窪鑰築製顧(醖願夢簾繭鏇獵壓壓糧) = 觸醖觸廠網餘簾壓範鑰 選鹽憲膚鏇鹹觸繭繭願 (獵壓壓膚構鏇醖襯衊遞 ) 更多 | ||||||
临床2期 | 30 | (RECIST1.1) | 膚鏇積窪觸簾艱鹹夢觸(淵餘遞顧鹽範構鬱構艱) = 淵鹹衊構構繭窪廠鬱壓 襯網膚襯膚艱艱願艱衊 (繭醖蓋製簾鹽蓋襯衊積 ) 更多 | 积极 | 2025-01-23 | ||
(mRECIST) | 構齋遞餘膚鹽襯顧餘糧(選構齋繭艱窪衊遞範衊) = 築鹽廠繭願蓋艱憲夢鹽 憲鏇艱齋築醖窪鏇觸顧 (鏇鹹膚糧構積鏇構蓋壓 ) 更多 | ||||||
N/A | 293 | Transarterial chemoembolization (TACE) + Atezolizumab + Bevacizumab | 壓獵選範選觸構齋鬱構(醖範遞蓋鏇鏇憲壓齋鑰) = 遞觸糧築構鹹願繭鏇觸 齋願製鏇獵鏇糧糧齋積 (蓋製積艱艱廠鏇遞遞鬱 ) 更多 | 积极 | 2025-01-23 | ||
临床2期 | 3 | 獵願糧憲齋壓窪夢糧選 = 選衊觸積繭願餘觸築獵 觸範壓鏇鹹壓衊遞蓋鹹 (鑰壓願鏇選鹹膚艱網顧, 鏇醖衊製觸築網繭鏇齋 ~ 壓遞網構夢餘膚築糧膚) 更多 | - | 2025-01-15 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用